Nearly 2 years after it voluntarily recalled Susvimo, Genentech recently announced plans to reintroduce the implant.
In July, the FDA approved a post-approval supplement to the biologics license application for Susvimo (ranibizumab injection 100 mg/mL), which continuously delivers a customized formulation of ranibizumab through the port delivery platform for the treatment of wet age-related macular degeneration. Susvimo is inserted during a one-time outpatient procedure and refilled every 6 months.
Healio spoke with Chris Brittain, senior vice president and global head of ophthalmology product